John A Zebala

6569598, May 27, 2003

Apr 17, 2001

09/836929

John A. Zebala - Redmond WA

Syntrix Biochip, Inc. - Redmond WA

G03C 173

4302701, 430326, 430906, 525420, 528324, 528332, 528335

Photoresist compositions and methods are provided for preparing photoresist films that are stable and impermeable to a broad range of organic solvents. Photoresist films provided herein may be photopatterned by selectively applying light, and may be stripped from a surface using unreactive agents. Photopatterned films may be used, for example, to selectively direct organic reagents to a solid support for the purpose of performing regionally selective solid-phase chemical synthesis with micron-scale resolution.

6951682, Oct 4, 2005

Sep 17, 1999

09/332815

John A. Zebala - Redmond WA, US

Syntrix Biochip, Inc. - Auburn WA

B32B003/10
B32B003/26
C12Q001/00
G01N033/53
G01N033/543

4283122, 4283216, 4283128, 4283157, 4283171, 428195, 435 4, 435 71, 435 77, 435 771, 435 772, 435 78, 435 79, 436518, 436519, 436523

Articles comprising substantially uniform porous coatings, which may be photopatterned, are provided. The use of such porous coatings increases the surface density of attached compounds within, for example, ligand arrays prepared by methods such as regionally selective solid-phase chemical synthesis. Arrays prepared using the porous coatings may be used within a variety of diagnostic and drug discovery assays.

7235660, Jun 26, 2007

Jan 2, 2007

11/619102

John A. Zebala - Auburn WA, US

C07D 475/00
C07D 475/08

544260

A process for the preparation of aminopterin with a purity greater than 90%, which comprises reacting folic acid, with a silazane in an organic solvent at a temperature from 60 to 180 C. , the said solvent being a tertiary amine organic solvent, or, if a catalyst which is acid in nature is present, a basic organic solvent or acetonitrile, and further adding water such that there is about 2. 8 to 7. 0 mole water for each mole of folic acid.

7312217, Dec 25, 2007

Mar 11, 2005

11/078271

John Anthony Zebala - Sammamish WA, US

Syntrix Biosystems, Inc. - Auburn WA

A61K 31/4985

514249

Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.

7612071, Nov 3, 2009

Mar 9, 2005

11/078614

Barton Aron Kamen - Princeton Junction NJ, US
Peter David Cole - Montclair NJ, US
Angela King Smith - West Windsor NJ, US
John Anthony Zebala - Sammamish WA, US

Syntrix Biosystems, Inc. - Auburn WA

A01N 43/54
A01N 43/60
A61K 31/4995
A61K 31/505

514249

The present invention relates to pharmaceutical compositions containing the antifolate aminopterin, processes for making the compositions, and methods of using them to treat disorders in adult and pediatric patients. Pharmaceutical compositions substantially free of impurities are provided comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof. Relative to the teachings of the prior art, the disclosed methods and compositions provide unexpected improvements that include a greater interpatient oral bioavailability in pediatric patients, a smaller interpatient coefficient of variation of oral bioavailability, a smaller mean intrapatient coefficient of variation of oral bioavailability, a greater therapeutic index, a smaller coefficient of variation of toxicity, efficacy in combination therapy, and efficacy of certain polyglutamated metabolites.

8129383, Mar 6, 2012

Oct 30, 2007

11/928890

John Zebala - Sammamish WA, US
Barton A. Kamen - Princeton Junction NJ, US

Aminopterin LLC - Auburn WA

A61K 31/505

514249, 514825, 514863, 514886, 514903

There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.

8349837, Jan 8, 2013

Jan 23, 2010

12/692593

John A. Zebala - Sammamish WA, US
Dean Y. Maeda - Seattle WA, US
Joel R. Morgan - Kent WA, US
Stuart J. Kahn - Seattle WA, US

Aminopterin, LLC - Auburn WA

A61K 31/495
A01N 43/58
A01N 43/60
C07D 475/00

514249, 544260

There is disclosed a pharmaceutical composition comprising racemic aminopterin or pharmaceutically acceptable salts thereof. There is further disclosed a method to treat a disorder in a patient comprising administering a therapeutically effective amount of racemic aminopterin or pharmaceutically acceptable salts of racemic aminopterin. More particularly, there is disclosed a method for treating disorders modulated by at least dihydrofolate reductase activity, such as cancers and inflammatory disorders, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of racemic aminopterin or a pharmaceutically acceptable salt thereof.

20040266808, Dec 30, 2004

Jun 28, 2004

10/878733

Barton Kamen - New Brunswick NJ, US
John Zebala - Sammamish WA, US

A61K031/485

514/282000

The present invention is a method of treating antifolate neurotoxicity in a mammal suffering from or at risk of developing antifolate neurotoxicity, which comprises administering to the mammal a therapeutically effective amount of an NMDA antagonist, or a pharmaceutically acceptable salt thereof.